Cancer, Refractory Cancer, Tumor, Solid
Conditions
Keywords
Cancer, Solid tumor, Malignant, Refractory, Resistant
Brief summary
This is a study of treatment with TBX-3400 in subjects with solid malignant tumors that are resistant or refractory to standard therapies. The subject's own blood cells are exposed to a protein that has been shown in the laboratory to result in anti-tumor activity. The study hypothesis is that TBX-3400 cells will enhance anti-tumor activity and improve the body's immune response to the tumor.
Interventions
BIOLOGICALTBX-3400
Autologous transfusion
Sponsors
Taiga Biotechnologies, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Subjects must meet all of the following inclusion criteria to be eligible for participation in the study: 1. Histologically or cytologically confirmed diagnosis of malignant solid tumor/s 2. Male or female subjects age 18 or older 3. Metastatic tumor that has failed at least one line of therapy with further options being non-curative; or with metastatic tumor and patient declines standard of care therapies and alternatives offered, at the discretion of the investigator 4. At least 28 days or 5 half-lives, since the last dose of medication to treat their malignancy. 5. Measurable or evaluable disease by RECIST version 1.1 6. Capable of understanding and complying with protocol requirements 7. A life expectancy of greater than 12 weeks at Screening 8. ECOG Performance Status of 0 to 2 9. Written informed consent from the patient or the patient's legally acceptable representative prior to the initiation of any study procedures 10. Adequate bone marrow, liver, and renal function at screening as defined below: * hemoglobin ≥8.0 g/dL (transfusions allowed) * total lymphocyte count ≥500/µL * absolute neutrophil count ≥1500/µL * platelet count ≥100,000/µL (transfusions allowed) * alanine transaminase and aspartate transaminase ≤3.0 times the upper limit of normal (ULN), or ≤5 times ULN for subjects with known hepatic metastases * total serum bilirubin ≤1.5 x the ULN; ≤2.0 x the ULN if liver metastases are present; subjects with a known history of Gilbert's syndrome (≤3.0 x the ULN) and/or isolated elevations of indirect bilirubin are eligible for study participation * estimated glomerular filtration rate ≥50 mL/min/1.73 m2 (using Cockcroft Gault formula)
Exclusion criteria
Subjects who meet any of the following criteria will not be eligible for participation in the study: 1. Pregnant or breast feeding 2. Require systemic pharmacologic doses of corticosteroids at or above the equivalent of 10 mg/day of prednisone; replacement doses, topical, ophthalmologic and inhalational steroids are permitted 3. Active, symptomatic central nervous system (CNS) metastases. Subjects with CNS metastases are eligible for the trial if the metastases have been treated by surgery and/or radiotherapy and the patient is off corticosteroids and is neurologically stable for at least 7 days prior to screening and the Medical Monitor approves subject inclusion 4. Any concurrent uncontrolled illness, including mental illness or substance abuse, which in the opinion of the investigator would make the patient unable to cooperate or participate in the trial 5. Severe uncontrolled cardiac disease within 3 months of study entry, including unstable or new onset angina, myocardial infarction or cerebrovascular accident 6. Women of child-bearing potential who are unable or unwilling to use an acceptable method of contraception 7. Known infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C (in USA: Known infection with human immunodeficiency virus \[HIV\], hepatitis B or hepatitis C that is not controlled and has any related symptoms) 8. Symptomatic congestive heart failure, defined as New York Heart Association Class II or higher 9. Systemic lupus erythematous (SLE), inflammatory bowel disease, primary Sjogren's syndrome, rheumatoid arthritis, systemic sclerosis, and granulomatosis with polyangiitis; and any other autoimmune condition that, in the opinion of the investigator, may increase the risk of trial participation or trial drug administration, unless reviewed and approved by the medical monitor. 10. Any hematopoietic malignancy 11. Have more than one primary cancer diagnosis within the last 3 years 12. Organ transplant or requiring immune suppression 13. Bullous pemphigoid and other autoimmune diseases of the dermal-epidermal junction; these include bullous pemphigoid, bullous SLE, liner IgA disease, epidermolysis bullosa acquisita, and other pemphigoid variants.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The primary endpoint is the incidence and severity of treatment-emergent adverse events (TEAEs), including the incidence of dose-limiting toxicities (DLTs), graded using the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. | 8 months | Adverse events from subject reporting |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Tumor Responses as defined by RECIST | 8 months | Tumor measurements to assess disease state |
| Assessment of concentrations of certain proteins such as cluster of differentiation 69 (CD69), as biomarkers of activity of TBX-3400 | 8 months | Preliminary efficacy assessment to measure activity of TBX-3400 |
| Presence and/or concentration of anti TBX-3400 antibodies | 8 months | Measure of immunogenicity of TBX-3400 |
Other
| Measure | Time frame | Description |
|---|---|---|
| Quantification of the concentration of interferon-gamma (IFN-γ) in plasma | 8 months | Preliminary efficacy assessment to measure activity of TBX-3400 |
| Quantification of the concentration of interleukin-1 (IL-1) in plasma | 8 months | Preliminary efficacy assessment to measure activity of TBX-3400 |
| Quantification of the concentration of transforming growth factor-beta (TGF-ß) in plasma | 8 months | Preliminary efficacy assessment to measure activity of TBX-3400 |
| Quantification of the concentration of interleukin-6 (IL-6) in plasma | 8 months | Preliminary efficacy assessment to measure activity of TBX-3400 |
| Quantification of the concentration of interferon-alpha (IFN-α) in plasma | 8 months | Preliminary efficacy assessment to measure activity of TBX-3400 |
| Quantification of the concentration of interferon-gamma inducible protein 10kD (IP-10) in plasma | 8 months | Preliminary efficacy assessment to measure activity of TBX-3400 |
Countries
Israel, United States
Contacts
Primary ContactYosef Refaeli
Backup ContactVivienne Margolis
Outcome results
None listed